Development of a novel SP-B peptide lung surfactant

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,962,218.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
2R44HL080775-04A1
Award Id:
n/a
Agency Tracking Number:
R44HL080775
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
2011 E. University Drive, Rancho Dominguez, CA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
58878682
Principal Investigator:
GARY FUJII
(310) 635-5502
gfujii@molecularexpress.com
Business Contact:
GARY FUJII
(310) 635-5502
gfujii@molecularexpress.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): This competitive renewal SBIR proposal extends our current Phase II translational research on novel synthetic lipid/peptide lung surfactants containing the highly active Super Mini-B (S-MB) peptide incorporating crucialfunctional regions of human surfactant protein (SP)-B, the most active apoprotein in biologic surfactant. Our initial Phase II grant focused on S-MB synthesized by solid-state chemistry, and documented the high activity of synthetic Minisurf surfactantcontaining solid-state S-MB combined with lipids. This renewal application continues the commercial development of Minisurf surfactant. This proposal will scale-up the production of the S-MB peptide and the Minisurf surfactant product, develop effective QA/QC methods for analyzing the S-MB peptide and Minisurf surfactant product, and demonstrate biological equivalency to laboratory research scale batches of Minisurf surfactant. Pilot lots of the Minisurf surfactant product will be manufactured andteste to ensure that the process is robust, the analytical controls are appropriate and the efficacy is maintained. Samples from selected pilot lots of Minisurf surfactant will be placed on stability and sent to a contractor to conduct GLP-compliant pharmacology and toxicology studies. The proposal also provides for active consultation with the FDA during the grant to facilitate successful IND preparation. Successful execution of these activities will lead to the development of a novel, commercially-attractive Minisurf synthetic surfactant product having significant advantages in manufacturing economy, activity, and inhibition resistance over current animal and synthetic surfactant drugs. PUBLIC HEALTH RELEVANCE: This SBIR competitive renewal grant will continue the development of a synthetic exogenous lung surfactant product having significant advantages in manufacture, activity and inhibition resistance compared to current drugs. This innovative surfactant product is expected to have great future utility in treating patients with severe acute respiratory failure from the neonatal respiratory distress syndrome (NRDS), clinical acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS). The synthetic surfactant in this grant canalso potentially be used in novel delivery systems for other pulmonary therapeutic agents such as antibiotics, anti-inflammatory drugs, or genetic materials (gene therapy).

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government